micro-community-banner
  • Saved
Therapeutic Response of Oral Chronic Graft-Versus-Host Disease to Topical Corticosteroids According to the 2014 National Institutes of Health (USA) Consensus Criteria

Therapeutic Response of Oral Chronic Graft-Versus-Host Disease to Topical Corticosteroids According to the 2014 National Institutes of Health (USA) Consensus Criteria

Source : https://pubmed.ncbi.nlm.nih.gov/37823294/

The oral cGVHD lesions and functional impacts improved within 6 months and 9 months, respectively. However, most of the patients required topical corticosteroid therapy for more than 1 year to...

The oral cGVHD lesions and functional impacts improved within 6 months and 9 months, respectively. However, most of the patients required topical corticosteroid therapy for more than 1 year to control their symptoms and lesions.

  • Saved
Risk Factors and Clinical Characteristics of Acute and Chronic Cutaneous Graft-Versus-Host Disease in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation

Risk Factors and Clinical Characteristics of Acute and Chronic Cutaneous Graft-Versus-Host Disease in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation

Source : https://pubmed.ncbi.nlm.nih.gov/37830789/

Acute and chronic cutaneous graft-versus-host disease (GVHD) are common complications following hematopoietic stem cell transplantation (HSCT) in pediatric patients. In this retrospective study, we explored the risk factors and clinical...

Our study highlights the importance of identifying and monitoring these high-risk patients to improve the clinical management and outcomes of cutaneous GVHD in pediatric HSCT recipients.

  • Saved
Adolescent and Young Adult Patients with Vaginal Graft-Versus-Host Disease and Hematocolpos Managed With Vaginal Stents: a Case Series

Adolescent and Young Adult Patients with Vaginal Graft-Versus-Host Disease and Hematocolpos Managed With Vaginal Stents: a Case Series

Source : https://pubmed.ncbi.nlm.nih.gov/37797789/

Vaginal stenosis secondary to vaginal GVHD should be considered in patients with a history of allogeneic HSCT presenting with amenorrhea, especially those with a diagnosis of primary ovarian insufficiency. The...

Vaginal stenosis secondary to vaginal GVHD should be considered in patients with a history of allogeneic HSCT presenting with amenorrhea, especially those with a diagnosis of primary ovarian insufficiency. The use of vaginal stents, along with postoperative medical and dilator management as appropriate, may prevent re-stenosis, although more...

  • Saved

The current study demonstrates superior FFS, OS and steroid tapering efficacy for ECP vs BAT as third-line therapy or beyond in cGvHD patients.

  • Saved
Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials

Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials

Source : https://aacrjournals.org/clincancerres/article-abstract/doi/10.1158/1078-0432.CCR-23-0666/729028/Targeting-Hedgehog-Signaling-with-Glasdegib-in?redirectedFrom=fulltext

AbstractPurpose:. Sclerotic chronic GVHD (scGVHD) is characterized by progressive skin fibrosis and frequent refractoriness to available therapies. Aberrant activation of Hedgehog signaling in dermal fibroblasts has been implicated in scGVHD....

Glasdegib demonstrated promising responses in patients with refractory scGVHD, but tolerability was limited by muscle cramping.